CXCR4 and cancer: A study utilized AMD3100 (also known as Plerixafor, which is clinically used in the treatment of leukemia for stabilizing hematopoietic stem cells) as an antagonist of CXCR4 against CAF-derived CXCL12/CXCR4 mediated signaling that facilitates invasion of cancer cells (Izumi et al., 2016).